T. T. Brown and M. J. Glesby, Management of the metabolic effects of HIV and HIV drugs, Nat Rev Endocrinol, vol.8, pp.11-21, 2011.

K. R. Feingold, R. M. Krauss, M. Pang, W. Doerrler, P. Jensen et al., The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B, J Clin Endocrinol Metab, vol.76, pp.1423-1427, 1993.

C. Grunfeld and K. R. Feingold, Metabolic disturbances and wasting in the acquired immunodeficiency syndrome, N Engl J Med, vol.327, pp.329-337, 1992.

S. A. Riddler, E. Smit, S. R. Cole, R. Li, J. S. Chmiel et al., Impact of HIV infection and HAART on serum lipids in men, JAMA, vol.289, pp.2978-2982, 2003.

M. Abifadel, M. Varret, J. P. Rabes, D. Allard, K. Ouguerram et al., Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, vol.34, pp.154-156, 2003.
DOI : 10.1038/ng1161

J. C. Cohen, E. Boerwinkle, T. H. Mosley, and H. H. Hobbs, Sequence variations in PCSK9, low LDL, and protection against coronary heart disease, N Engl J Med, vol.354, pp.1264-1272, 2006.
DOI : 10.1056/nejmoa054013

N. G. Seidah, Z. Awan, M. Chretien, and M. Mbikay, PCSK9: a key modulator of cardiovascular health, Circ Res, vol.114, pp.1022-1036, 2014.

B. Cariou, K. Si-tayeb, L. May, and C. , Role of PCSK9 beyond liver involvement, Curr Opin Lipidol, vol.26, pp.155-161, 2015.
DOI : 10.1097/mol.0000000000000180
URL : https://hal.archives-ouvertes.fr/hal-01830980

M. Farnier, Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experience, Curr Opin Lipidol, vol.27, pp.597-604, 2016.
DOI : 10.1097/mol.0000000000000356

M. S. Sabatine, R. P. Giugliano, A. C. Keech, N. Honarpour, S. D. Wiviott et al., Evolocumab and clinical outcomes in patients with cardiovascular disease, N Engl J Med, vol.376, pp.1713-1722, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01896445

K. R. Feingold, A. H. Moser, J. K. Shigenaga, S. M. Patzek, and C. Grunfeld, Inflammation stimulates the expression of PCSK9, Biochem Biophys Res Commun, vol.374, pp.341-344, 2008.
DOI : 10.1016/j.bbrc.2008.07.023
URL : http://europepmc.org/articles/pmc2571081?pdf=render

J. H. Boyd, C. D. Fjell, J. A. Russell, D. Sirounis, M. S. Cirstea et al., Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis, J Innate Immun, vol.8, pp.211-220, 2016.

P. Kohli, P. Ganz, Y. Ma, R. Scherzer, S. Hur et al., HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent 'PCSK9-Lipid Paradox, J Am Heart Assoc, vol.5, p.2683, 2016.
DOI : 10.1161/jaha.115.002683
URL : https://www.ahajournals.org/doi/pdf/10.1161/JAHA.115.002683

P. Costet, M. M. Hoffmann, B. Cariou, B. Guyomarc'h-delasalle, K. T. Winkler et al., Plasma PCSK9 is increased by fenofibrate and atorvastatin in a nonadditive fashion in diabetic patients, Atherosclerosis, vol.212, pp.246-251, 2010.
DOI : 10.1016/j.atherosclerosis.2010.05.027

R. Dray-spira, C. Legeai, L. Den, M. Boue, F. Lascoux-combe et al., Burden of HIV disease and comorbidities on the chances of maintaining employment in the era of sustained combined antiretoviral therapies use, AIDS, vol.26, pp.207-215, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00677161

D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher et al., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, vol.28, pp.412-419, 1985.

M. Ruscica, C. Ricci, C. Macchi, P. Magni, R. Cristofani et al., Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line, J Biol Chem, vol.291, pp.3508-3519, 2016.

E. Topchiy, M. Cirstea, H. J. Kong, J. H. Boyd, Y. Wang et al., Lipopolysaccharide is cleared from the circulation by hepatocytes via the low density lipoprotein receptor, PLoS One, vol.11, p.155030, 2016.

D. J. Dwivedi, P. M. Grin, M. Khan, A. Prat, J. Zhou et al., Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis, Shock, vol.46, pp.672-680, 2016.

L. Bras, M. Roquilly, A. Deckert, V. Langhi, C. Feuillet et al., Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury, J Clin Endocrinol Metab, vol.98, pp.732-736, 2013.

K. R. Walley, K. R. Thain, J. A. Russell, M. P. Reilly, N. J. Meyer et al., PCSK9 is a critical regulator of the innate immune response and septic shock outcome, Sci Transl Med, vol.6, pp.258-143, 2014.

A. Baruch, S. Mosesova, J. D. Davis, N. Budha, A. Vilimovskij et al., Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the Phase 2 EQUATOR Study), Am J Cardiol, vol.119, pp.1576-1583, 2017.

H. J. Jeong, H. S. Lee, K. S. Kim, Y. K. Kim, D. Yoon et al., Steroldependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein

, J Lipid Res, vol.49, pp.399-409, 2008.

X. M. Sun, E. R. Eden, I. Tosi, C. K. Neuwirth, D. Wile et al., Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia, Hum Mol Genet, vol.14, pp.1161-1169, 2005.

H. Sun, A. Samarghandi, N. Zhang, Z. Yao, M. Xiong et al., Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor, Arterioscler Thromb Vasc Biol, vol.32, pp.1585-1595, 2012.

K. Ouguerram, M. Chetiveaux, Y. Zair, P. Costet, M. Abifadel et al., Apolipoprotein B100 metabolism in autosomaldominant hypercholesterolemia related to mutations in PCSK9, Arterioscler Thromb Vasc Biol, vol.24, pp.1448-1453, 2004.

P. Costet, B. Cariou, G. Lambert, F. Lalanne, B. Lardeux et al., Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c, J Biol Chem, vol.281, pp.6211-6218, 2006.

J. Miao, P. V. Manthena, M. E. Haas, A. V. Ling, D. J. Shin et al., Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9, Arterioscler Thromb Vasc Biol, vol.35, pp.1589-1596, 2015.

B. Cariou, C. Langhi, L. Bras, M. Bortolotti, M. Le et al., Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets, Nutr Metab, vol.10, p.4, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00778104

S. G. Lakoski, T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs, Genetic and metabolic determinants of plasma PCSK9 levels, J Clin Endocrinol Metab, vol.94, pp.2537-2543, 2009.

A. Baass, G. Dubuc, M. Tremblay, E. E. Delvin, J. O'loughlin et al., Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents, Clin Chem, vol.55, pp.1637-1645, 2009.

A. F. Schmidt, D. I. Swerdlow, M. V. Holmes, R. S. Patel, Z. Fairhursthunter et al., PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study, Lancet Diabetes Endocrinol, vol.5, pp.97-105, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01833114

B. A. Ference, J. G. Robinson, R. D. Brook, A. L. Catapano, M. J. Chapman et al., Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes, N Engl J Med, vol.375, pp.2144-2153, 2016.

L. A. Lotta, S. J. Sharp, S. Burgess, J. R. Perry, I. D. Stewart et al., Association between low-density lipoprotein cholesterollowering genetic variants and risk of type 2 diabetes: a metaanalysis, JAMA, vol.316, pp.1383-1391, 2016.